ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Enhanced inflammatory and oxidative response mitigation by acetyl-L-carnitine in a rat model of pelvic inflammatory disease.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inverse Association Between Composite Dietary Antioxidant Index and Prevalence of Pelvic Inflammatory Disease Among Women: A Cross-Sectional Study of NHANES 2013-2018.Healthcare (Basel, Switzerland) · 2026Article
- Current methods and mechanisms for animal models of pelvic inflammatory disease: a review.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Acetyl-L-carnitine (ALC) is known for its potent antioxidant and anti-inflammatory properties. This research aimed to investigate the properties of ALC in combating pelvic inflammatory disease (PID) in a rat model. PID, a consequence of sexually transmitted infections in females, can impact the fallopian tubes and uterus, leading to complications. This study is a randomized control preclinical experiment. A total of 24 reproductively mature Sprague Dawley female rats were randomly and equally assigned (n = 4 per group) to six cohorts: control, PID, low-dose prophylactic, high-dose prophylactic, and low-dose therapeutic and high-dose therapeutic groups. PID was induced by injecting the rat cervix with a multi-pathogen solution. Acetyl-L-carnitine, 100 mg/kg (once a day), was orally administered to rats in the low-dose prophylactic group, while 200 mg/kg (once a day) to the high-dose prophylactic group, starting 1 day prior to induction of PID. The therapeutic groups were given similar doses of ALC 1 day after the PID model was confirmed. Samples from the right upper genital tract were collected for ELISA and antioxidant assays, while the left upper genital tract samples underwent histopathological analysis. According to the results, the ALC-treated groups showed a decreased level of cytokines (IL-1β, TNF-α) and oxidative stress markers (catalase, lipid peroxidation) when compared to the PID group. Histopathological examinations revealed that ALC treatment reduced the infiltration of neutrophils and lymphocytes in the uterus compared to the PID group. It was concluded that ALC showed potential antioxidant and anti-inflammatory effects in PID and, therefore, could be used as a possible option for the treatment of PID.
Indexed as
Identifiers
39912899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.